Hjem › Brystkreft › Michigan › Detroit
Kliniske studier for Brystkreft i Detroit, MI
33 studier for Brystkreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RekruttererFase 2
- Henry Ford Hospital, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekruttererFase 3
- Henry Ford Health ( Site 0002), Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruttererFase 3
- Research Site, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutterer
- Karmanos Cancer Center - Wayne State University, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RekruttererFase 3
- Henry Ford Hospital, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RekruttererFase 3
- Karmanos Cancer Center, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RekruttererFase 1/2
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekruttererFase 1/2
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RekruttererFase 3
- Henry Ford Health System, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Rekrutterer
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
E-Mindfulness Approaches for Living After Breast Cancer
RekruttererFase 3
- Henry Ford Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
RekruttererFase 1/2
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RekruttererFase 3
- Henry Ford Health System, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
Rekrutterer
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekruttererFase 1/2
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
F-Tryptophan PET/CT in Human Cancers
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Rekrutterer
- Karmanos Cancer Institute, Detroit
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
- Akut myelogen leukemi14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.